{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:31:30Z","timestamp":1724459490318},"reference-count":42,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n               <jats:title>Background<\/jats:title>\n               <jats:p>To explore the efficacy and safety of etrolizumab in treating inflammatory bowel disease (IBD) through meta-analysis.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Method<\/jats:title>\n               <jats:p>A comprehensive exploration encompassed randomized controlled trials examining the efficacy of etrolizumab in treating IBD across PubMed, Embase, Cochrane library, and Web of Science, with a search deadline of 1 December 2023. Quality assessment leaned on the Cochrane manual\u2019s risk-of-bias evaluation, while Stata 15 undertook the data analysis.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Result<\/jats:title>\n               <jats:p>Five randomized controlled studies involving 1682 individuals were finally included, Meta-analysis results suggested that compared with placebo, etrolizumab could improve clinical response (RR = 1.26, 95% CI [1.04\u20131.51]), clinical remission (RR = 1.26, 95% CI [1.04\u20131.51]) in IBD patients. Endoscopic alleviate (RR = 2.10, 95% CI [1.56\u20132.82]), endoscopic improvement (RR = 2.10, 95% CI [1.56\u20132.82]), endoscopic remission (RR = 2.10, 95% CI [1.56\u20132.82]), Endoscopic improvement (RR = 1.56, 95% CI [1.30\u20131.89]), histological remission (RR = 1.62, 95% CI [1.26\u20132.08]), and did not increase any adverse events (RR = 0.95, 95% CI [0.90\u20131.01]) and serious adverse events (RR = 0.94, 95% CI [0.68\u20131.31]).<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Conclusion<\/jats:title>\n               <jats:p>According to our current study, etrolizumab is a promising drug in IBD.<\/jats:p>\n            <\/jats:sec>","DOI":"10.7717\/peerj.17945","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T15:24:45Z","timestamp":1724426685000},"page":"e17945","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of etrolizumab in the treatment of inflammatory bowel disease: a meta-analysis"],"prefix":"10.7717","volume":"12","author":[{"given":"Yong gang","family":"Dai","sequence":"first","affiliation":[{"name":"Shandong University of Traditional Chinese Medicine, Shandong, China"},{"name":"Shandong Provincial Third Hospital, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dajuan","family":"Sun","sequence":"additional","affiliation":[{"name":"Shandong University of Traditional Chinese Medicine, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Liu","sequence":"additional","affiliation":[{"name":"Shandong University of Traditional Chinese Medicine, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiunan","family":"Wei","sequence":"additional","affiliation":[{"name":"Shandong University of Traditional Chinese Medicine, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Chi","sequence":"additional","affiliation":[{"name":"Shandong University of Traditional Chinese Medicine, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongya","family":"Wang","sequence":"additional","affiliation":[{"name":"Shandong Provincial Third Hospital, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4443","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"key":"10.7717\/peerj.17945\/ref-1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/j.gastro.2021.04.063","article-title":"Approach to the management of recently diagnosed inflammatory bowel disease patients: a user\u2019s guide for adult and pediatric gastroenterologists","volume":"161","author":"Agrawal","year":"2021","journal-title":"Gastroenterology"},{"key":"10.7717\/peerj.17945\/ref-2","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.7717\/peerj.17945\/ref-3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jaad.2020.07.041","article-title":"Isotretinoin and risk of inflammatory bowel disease: more data to support lack of meaningful risk","volume":"84","author":"Barbieri","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.7717\/peerj.17945\/ref-4","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1056\/NEJMra1907607","article-title":"Newer biologic and small-molecule therapies for inflammatory bowel disease","volume":"385","author":"Baumgart","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.7717\/peerj.17945\/ref-5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41575-022-00634-6","article-title":"Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment","volume":"19","author":"Bisgaard","year":"2022","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.7717\/peerj.17945\/ref-6","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.cgh.2008.06.007","article-title":"Treatment of active Crohn\u2019s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin","volume":"6","author":"Feagan","year":"2008","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.7717\/peerj.17945\/ref-7","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa042982","article-title":"Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin","volume":"352","author":"Feagan","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.7717\/peerj.17945\/ref-8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1177\/1756283x16647935","article-title":"The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes","volume":"9","author":"Fiorino","year":"2016","journal-title":"Therapeutic Advances in Gastroenterology"},{"key":"10.7717\/peerj.17945\/ref-9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1046\/j.1365-2036.2002.01205.x","article-title":"A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin","volume":"16","author":"Gordon","year":"2002","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.7717\/peerj.17945\/ref-10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2147\/ceg.S293272","article-title":"Anti-integrins for the treatment of inflammatory bowel disease: current evidence and perspectives","volume":"14","author":"Gubatan","year":"2021","journal-title":"Clinical and Experimental Gastroenterology"},{"key":"10.7717\/peerj.17945\/ref-11","doi-asserted-by":"publisher","first-page":"114101","DOI":"10.1016\/j.addr.2021.114101","article-title":"Advances in the treatment of inflammatory bowel disease: focus on polysaccharide nanoparticulate drug delivery systems","volume":"181","author":"Hadji","year":"2022","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.7717\/peerj.17945\/ref-12","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.7717\/peerj.17945\/ref-13","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1084\/jem.20080414","article-title":"Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans","volume":"205","author":"Jaensson","year":"2008","journal-title":"Journal of Experimetnal Medicine"},{"key":"10.7717\/peerj.17945\/ref-14","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1084\/jem.20051100","article-title":"Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing","volume":"202","author":"Johansson-Lindbom","year":"2005","journal-title":"Journal of Experimetnal Medicine"},{"key":"10.7717\/peerj.17945\/ref-15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fphar.2019.00039","article-title":"Cellular mechanisms of etrolizumab treatment in inflammatory bowel disease","volume":"10","author":"Lichnog","year":"2019","journal-title":"Frontiers in Pharmacology"},{"key":"10.7717\/peerj.17945\/ref-16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1517\/14712598.2016.1158807","article-title":"Etrolizumab for ulcerative colitis: the new kid on the block?","volume":"16","author":"Makker","year":"2016","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"Suppl 1","key":"10.7717\/peerj.17945\/ref-17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000507782","article-title":"Emerging treatment options in inflammatory bowel disease: janus kinases, stem cells, and more","volume":"101","author":"Misselwitz","year":"2020","journal-title":"Digestion"},{"key":"10.7717\/peerj.17945\/ref-18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.phrs.2018.11.003","article-title":"Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: a systematic review and indirect comparison","volume":"139","author":"Motaghi","year":"2019","journal-title":"Pharmacological Research"},{"key":"10.7717\/peerj.17945\/ref-19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ijbiomac.2022.12.032","article-title":"Multifunctional hydrogels based on chitosan, hyaluronic acid and other biological macromolecules for the treatment of inflammatory bowel disease: a review","volume":"227","author":"Ouyang","year":"2023","journal-title":"International Journal of Biological Macromolecules"},{"key":"10.7717\/peerj.17945\/ref-20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"10.7717\/peerj.17945\/ref-21","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/ibd\/izy269","article-title":"Cell trafficking interference in inflammatory bowel disease: therapeutic interventions based on basic pathogenesis concepts","volume":"25","author":"P\u00e9rez-Jeldres","year":"2019","journal-title":"Inflammatory Bowel Disease"},{"key":"10.7717\/peerj.17945\/ref-22","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2468-1253(21)00298-3","article-title":"Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial","volume":"7","author":"Peyrin-Biroulet","year":"2022","journal-title":"The Lancet Gastroenterology and Hepatology"},{"key":"10.7717\/peerj.17945\/ref-23","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1053\/j.gastro.2022.01.024","article-title":"Disease monitoring in inflammatory bowel disease: evolving principles and possibilities","volume":"162","author":"Plevris","year":"2022","journal-title":"Gastroenterology"},{"key":"10.7717\/peerj.17945\/ref-24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12916-019-1323-8","article-title":"Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview","volume":"17","author":"Pouillon","year":"2019","journal-title":"BMC Medicine"},{"key":"10.7717\/peerj.17945\/ref-25","doi-asserted-by":"publisher","first-page":"Cd011661","DOI":"10.1002\/14651858.CD011661.pub2","article-title":"Etrolizumab for induction of remission in ulcerative colitis","volume":"2015","author":"Rosenfeld","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.7717\/peerj.17945\/ref-26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(21)00338-1","article-title":"Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials","volume":"7","author":"Rubin","year":"2022","journal-title":"The Lancet Gastroenterology and Hepatology"},{"key":"10.7717\/peerj.17945\/ref-27","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1136\/gutjnl-2011-301769","article-title":"A randomised phase I study of etrolizumab (rhuMAb \u03b27) in moderate to severe ulcerative colitis","volume":"62","author":"Rutgeerts","year":"2013","journal-title":"Gut"},{"key":"10.7717\/peerj.17945\/ref-28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000342742","article-title":"The future of inflammatory bowel disease therapy: where do we go from here?","volume":"30","author":"Sandborn","year":"2012","journal-title":"Digestive Diseases"},{"key":"10.7717\/peerj.17945\/ref-29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/s2468-1253(22)00303-x","article-title":"Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn\u2019s disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial","volume":"8","author":"Sandborn","year":"2023","journal-title":"Lancet Gastroenterology & Hepatology"},{"key":"10.7717\/peerj.17945\/ref-30","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/s2468-1253(21)00097-2","article-title":"The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease","volume":"6","author":"Sasson","year":"2021","journal-title":"The Lancet Gastroenterology and Hepatology"},{"key":"10.7717\/peerj.17945\/ref-31","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1080\/13543784.2021.1974396","article-title":"Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents","volume":"30","author":"Solitano","year":"2021","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.7717\/peerj.17945\/ref-32","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/apt.14631","article-title":"Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-\u03b27 integrin therapy for inflammatory bowel disease","volume":"47","author":"Tang","year":"2018","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.7717\/peerj.17945\/ref-33","doi-asserted-by":"publisher","first-page":"243","DOI":"10.20524\/aog.2016.0027","article-title":"Advances in the development of new biologics in inflammatory bowel disease","volume":"29","author":"Ungar","year":"2016","journal-title":"Annals of Gastroenterology"},{"key":"10.7717\/peerj.17945\/ref-34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S2468-1253(21)00295-8","article-title":"Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study","volume":"7","author":"Vermeire","year":"2022","journal-title":"The Lancet Gastroenterology and Hepatology"},{"key":"10.7717\/peerj.17945\/ref-35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s0140-6736(14)60661-9","article-title":"Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial","volume":"384","author":"Vermeire","year":"2014","journal-title":"Lancet"},{"key":"10.7717\/peerj.17945\/ref-36","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00535-018-1449-z","article-title":"New treatment options for inflammatory bowel diseases","volume":"53","author":"Verstockt","year":"2018","journal-title":"Journal of Gastroenterology"},{"key":"10.7717\/peerj.17945\/ref-37","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/s2468-1253(22)00047-4","article-title":"Inflammatory bowel disease in sub-Saharan Africa: epidemiology, risk factors, and challenges in diagnosis","volume":"7","author":"Watermeyer","year":"2022","journal-title":"The Lancet Gastroenterology and Hepatology"},{"key":"10.7717\/peerj.17945\/ref-38","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1007\/s12325-018-0795-9","article-title":"Emerging therapies for inflammatory bowel disease","volume":"35","author":"Weisshof","year":"2018","journal-title":"Advances in Therapy"},{"key":"10.7717\/peerj.17945\/ref-39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.gastro.2022.10.024","article-title":"Fibrosis and inflammation in inflammatory bowel disease-more than 2 sides of the same coin?","volume":"164","author":"Welz","year":"2023","journal-title":"Gastroenterology"},{"key":"10.7717\/peerj.17945\/ref-40","doi-asserted-by":"publisher","first-page":"698","DOI":"10.15585\/mmwr.mm7019a2","article-title":"Prevalence of inflammatory bowel disease among medicare fee-for-service beneficiaries\u2014United States, 2001\u20132018","volume":"70","author":"Xu","year":"2021","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"10.7717\/peerj.17945\/ref-41","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/ecco-jcc\/jjab029","article-title":"The burden of inflammatory bowel disease in Europe in 2020","volume":"15","author":"Zhao","year":"2021","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.7717\/peerj.17945\/ref-42","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3389\/fimmu.2017.00891","article-title":"Anti-adhesion therapies in inflammatory bowel disease-molecular and clinical aspects","volume":"8","author":"Zundler","year":"2017","journal-title":"Frontiers in Immunology"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/17945.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/17945.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/17945.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/17945.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T15:24:52Z","timestamp":1724426692000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/17945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":42,"alternative-id":["10.7717\/peerj.17945"],"URL":"https:\/\/doi.org\/10.7717\/peerj.17945","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]},"article-number":"e17945"}}